Biomedomics launches igm-igg rapid test for novel
by hospimedica international staff writers
posted on 14 mar 2020
biomedomics, inc. (morrisville, nc, usa) has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of infection. The new rapid igm-igg combined antibody test for is used to qualitatively detect igg and igm antibodies of the novel in human serum, plasma or whole blood in vitro. These proteins indicate that a person’s immune system has responded to infection with the It is one of the world’s first rapid tests for utilizing this technology.
Recent studies suggest that a high percentage of patients show no clinical symptoms of the , which makes screening patients vitally important. The test can be used for rapid screening of carriers that are symptomatic or asymptomatic. By using biomarkers from the body’s imm